Search clinical trials for: SHR6390 anatrozole

Total 408 results

Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Breast Cancer

China
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Advanced Solid Tumor Patients

Neoplasm

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Atridia Pty Ltd.

Completed

A Trial of SHR6390 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

ER-Positive, HER2-Negative Breast Cancer

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Food Effect Study of Anaprazole in Healthy Chinese Subjects

Healthy Male Volunteers
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Advanced Solid Tumor

China
Baylor College of Medicine

Completed

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

Hypogonadism | Severe Obesity

United States
AstraZeneca

Completed

ATAC - Arimidex, Tamoxifen Alone or in Combination

Breast Cancer
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Healthy Male Volunteers
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
AstraZeneca

Completed

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Breast Cancer

Sweden, Czech Republic, France, Spain, United Kingdom, Hungary, Portugal
University of Kansas Medical Center
AstraZeneca

Completed

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Invasive Breast Cancer

United States
Centre for Endocrinology and Reproductive Medicine...

Completed

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Endometriosis

Italy
Henan Cancer Hospital

Active, not recruiting

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)

Stage I Breast Cancer

United States, Canada, Hong Kong
The Affiliated Hospital of Qingdao University

Unknown

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition

Healthy Volunteers

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Teva Pharmaceuticals USA

Completed

Anastrozole 1 mg Tablets Under Fasting Conditions

Healthy

Canada
Thomas Jefferson University
Context Therapeutics Inc.

Active, not recruiting

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Refractory Endometrial Carcinoma | Refractory Endometrial Endometrioid Adenocarcinoma | Refractory Endometrial Adenocarcinoma | Refractory Endometrial Clear Cell Adenocarcinoma | Refractory Endometrial Mixed Cell Adenocarcinoma | Refractory Endometrial Serous Adenocarcinoma | Refractory Endometrial...

United States
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects

Healthy Male Volunteers
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Healthy Volunteers

Search clinical trials for: SHR6390 anatrozole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations